Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11623789 | 0.85 | HPGD (0.43) | KCNH2 | |
| SCHEMBL11123090 | 0.84 | KIF11 (0.51) | PTGS2PTGS1KIF11 | |
| SCHEMBL11625367 | 0.82 | KIF11 (0.54) | PTGS2KIF11 | |
| SCHEMBL8596418 | 0.81 | PTGS2 (0.46) | PTGS2PTGS1 | |
| SCHEMBL8908072 | 0.81 | PTGS2 (0.56) | PTGS2KCNH2PTGS1MAP4K4PIK3CA | |
| SCHEMBL27731893 | 0.80 | NPBWR1 (0.44) | PTGS2PTGS1 | |
| SCHEMBL5597397 | 0.79 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL7144668 | 0.79 | PTGS2 (0.49) | PTGS2KCNH2PTGS1MAP4K4PIK3CA | |
| SCHEMBL8797359 | 0.78 | GFER (0.50) | KCNH2KIF11 | |
| SCHEMBL26093883 | 0.78 | KDM4E (0.44) | MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140181-A1 | COMBINATION THERAPY OF RADIATION AND A COX-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| JP-2001503395-A | — | — | 2001-03-13 | — | — | JP | claimed |
| WO-2000038716-A9 | COMBINATION THERAPY OF RADIATION AND A COX-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | SEARLE & CO (US) | 2000-11-30 | — | — | WO | claimed |
| WO-2000038716-A1 | COMBINATION THERAPY OF RADIATION AND A COX-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| EP-0932402-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1999-08-04 | — | — | EP | claimed |
| WO-1998016227-A9 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | — | 1998-07-30 | — | — | WO | claimed |
| WO-1998016227-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1998-04-23 | — | — | WO | claimed |
| WO-2005020926-A2 | TREATMENT OR PREVENTION OF VASCULAR DISORDERS WITH COX-2 INHIBITORS IN COMBINATION WITH CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1365753-A2 | UROGUANYLIN AND CYCLOOXYGENASE-2 INHIBITOR COMBINATIONS FOR INHIBITION OF INTESTINAL CANCER | Pharmacia Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002062369-A2 | UROGUANYLIN AND CYCLOOXYGENASE-2 INHIBITOR COMBINATIONS FOR INHIBITION OF INTESTINAL CANCER | PHARMACIA CORPORATION (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-0979077-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS | G.D. Searle & Co. (US) | 2000-02-16 | — | — | EP | disclosed |
| EP-0932402-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998047509-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998016227-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1998-04-23 | — | — | WO | disclosed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | disclosed |